The role of melanocyte-stimulating hormone in insulin resistance and type 2 diabetes mellitus

Treatments in Endocrinology

Volumn 5, Issue 1, 2006, Pages 7-13

  Costa, Jessica Lynn ^a   Hochgeschwender, Ute ^b   Brennan, Miles ^a  

^a UNIVERSITY OF DENVER   (United States)

^b OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; ARGININE; GLUCOSE; HISTIDINE; INSULIN; INTERMEDIN; LEPTIN; MELANOCORTIN; MELANOCORTIN RECEPTOR; PEPTIDE HORMONE; PHENYLALANINE; PROAPIOMELANOCORTIN; PROTEIN PRECURSOR; TRYPTOPHAN; UNCLASSIFIED DRUG; ALPHA INTERMEDIN; PROOPIOMELANOCORTIN;

AMINO ACID SEQUENCE; BODY WEIGHT; CENTRAL NERVOUS SYSTEM; DIET; ENDOCRINE SYSTEM; FOOD INTAKE; GENETIC DISORDER; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN TOLERANCE TEST; METABOLIC RATE; METABOLIC SYNDROME X; MOUSE STRAIN; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PERIPHERAL CIRCULATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PROCESSING; REVIEW; RISK FACTOR; TISSUE SPECIFICITY; WEIGHT CONTROL; WEIGHT GAIN; WEIGHT REDUCTION; ANIMAL; CHEMISTRY; METABOLISM;

ALPHA-MSH; ANIMALS; DIABETES MELLITUS, TYPE 2; HUMANS; INSULIN RESISTANCE; MELANOCYTE-STIMULATING HORMONES; PRO-OPIOMELANOCORTIN;

EID: 30744431606     PISSN: 11756349     EISSN: 11756349     Source Type: Journal    
DOI: 10.2165/00024677-200605010-00002     Document Type: Review

References (50)

1. Flegal KM, Carroll MD, Ogden CL, et al. Prevalence and trends in obesity among US adults 1999-2000. JAMA 2002; 288 (14): 1723-7
2. Larsen PR, Kronenberg HM, Melmed S, et al. editors. Williams textbook of endocrinology. 10th ed. Philadelphia (PA): WB Saunders Company, 2003
3. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27 (5): 1047-53
4. Hogan P, Dall T, Nikolov P. Economic costs of diabetes in the US in 2002. Diabetes Care 2003; 26 (3): 917-32
5. Greenberg AS, McDaniel ML. Identifying the links between obesity, insulin resistance and beta-cell function: potential role of adipocyte-derived cytokines in the pathogenesis of type 2 diabetes. Eur J Clin Invest 2002; 32 Suppl. 3: 24-34
6. Shaw DI, Hall WL, Williams CM. Metabolic syndrome: what is it and what are the implications? Proc Nutr Soc 2005; 64 (3): 349-57
7. World Health Organization. Fact sheet no. 138, April 2002 [online]. Available from URL: http://www.who.int/mediacentre/factsheets/fs136/en/index. html [Accessed 2005 Oct 12]
8. Eckel RH, York DA, Rossner S, et al. Prevention Conference VII: obesity, a worldwide epidemic related to heart disease and stroke: executive summary. Circulation 2004; 110 (18): 2968-75
9. Krude H, Biebermann H, Luck W, et al. Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans. Nat Genet 1998; 19 (2): 155-7
10. Krude H, Biebermann H, Schnabel D, et al. Obesity due to proopiomelanocortin deficiency: three new cases and treatment trials with thyroid hormone and ACTH4-10. J Clin Endocrinol Metab 2003; 88 (10): 4633-40
11. Montague CT, Farooqi IS, Whitehead JP, et al. Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature 1997; 387 (6636): 903-8
12. Clement K, Vaisse C, Lahlou N, et al. A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction. Nature 1998; 392 (6674): 398-401
13. Hinney A, Becker I, Heibult O, et al. Systematic mutation screening of the pro- opiomelanocortin gene: identification of several genetic variants including three different insertions, one nonsense and two missense point mutations in probands of different weight extremes. J Clin Endocrinol Metab 1998; 83 (10): 3737-41
14. Lahlou N, Issad T, Lebouc Y, et al. Mutations in the human leptin and leptin receptor genes as models of serum leptin receptor regulation. Diabetes 2002; 51 (6): 1980-5
15. Farooqi IS, Jebb SA, Langmack G, et al. Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med 1999; 341 (12): 879-84
16. Challis BG, Pritchard LE, Creemers JW, et al. A missense mutation disrupting a dibasic prohormone processing site in pro-opiomelanocortin (POMC) increases susceptibility to early-onset obesity through a novel molecular mechanism. Hum Mol Genet 2002; 11 (17): 1997-2004
17. Yeo GS, Farooqi IS, Aminian S, et al. A frameshift mutation in MC4R associated with dominantly inherited human obesity [letter]. Nat Genet 1998; 20 (2): 111-2
18. Yeo GS, Lank EJ, Farooqi IS, et al. Mutations in the human melanocortin-4 receptor gene associated with severe familial obesity disrupts receptor function through multiple molecular mechanisms. Hum Mol Genet 2003; 12 (5): 561-74
19. Farooqi IS, Keogh JM, Yeo GS, et al. Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene. N Engl J Med 2003; 348 (12): 1085-95
20. Farooqi IS, Yeo GS, Keogh JM, et al. Dominant and recessive inheritance of morbid obesity associated with melanocortin 4 receptor deficiency. J Clin Invest 2000; 106 (2): 271-9
21. Gu W, Tu Z, Kleyn PW, et al. Identification and functional analysis of novel human melanocortin-4 receptor variants. Diabetes 1999; 48 (3): 635-9
22. Lubrano-Berthelier C, Durand E, Dubern B, et al. Intracellular retention is a common characteristic of childhood obesity-associated MC4R mutations. Hum Mol Genet 2003; 12 (2): 145-53
23. Ma L, Tataranni PA, Bogardus C, et al. Melanocortin 4 receptor gene variation is associated with severe obesity in Pima Indians. Diabetes 2004; 53 (10): 2696-9
24. Mergen M, Mergen H, Ozata M, et al. A novel melanocortin 4 receptor (MC4R) gene mutation associated with morbid obesity. J Clin Endocrinol Metab 2001; 86 (7): 3448-51
25. Lee YS, Poh LK, Loke KY. A novel melanocortin 3 receptor gene (MC3R) mutation associated with severe obesity. J Clin Endocrinol Metab 2002; 87 (3): 1423-6
26. Tao YX. Molecular mechanisms of the neural melanocortin receptor dysfunction in severe early onset obesity. Mol Cell Endocrinol 2005; 239 (1-2): 1-14
27. Yaswen L, Diehl N, Brennan MB, et al. Obesity in the mouse model of pro-opiomelanocortin deficiency responds to peripheral melanocortin. Nat Med 1999; 5 (9): 1066-70
28. Butler AA, Kesterson RA, Khong K, et al. A unique metabolic syndrome causes obesity in the melanocortin-3 receptor-deficient mouse. Endocrinology 2000; 141 (9): 3518-21
29. Chen AS, Marsh DJ, Trumbauer ME, et al. Inactivation of the mouse melanocortin-3 receptor results in increased fat mass and reduced lean body mass. Nat Genet 2000; 26 (1): 97-102
30. Huszar D, Lynch CA, Fairchild-Huntress V, et al. Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell 1997; 88 (1): 131-41
31. Hochgeschwender U, Costa JL, Reed P, et al. Altered glucose homeostasis in proopiomelanocortin-null mouse mutants lacking central and peripheral melanocortin. Endocrinology 2003; 144 (12): 5194-202
32. Pierroz DD, Ziotopoulou M, Ungsunan L, et al. Effects of acute and chronic administration of the melanocortin agonist MTII in mice with diet-induced obesity. Diabetes 2002; 51 (5): 1337-45
33. Marsh DJ, Hollopeter G, Huszar D, et al. Response of melanocortin-4 receptor-deficient mice to anorectic and orexigenic peptides. Nat Genet 1999; 21 (1): 119-22
34. Fan W, Dinulescu DM, Butler AA, et al. The central melanocortin system can directly regulate serum insulin levels. Endocrinology 2000; 141 (9): 3072-9
35. Bluher S, Ziotopoulou M, Bullen Jr JW, et al. Responsiveness to peripherally administered melanocortins in lean and obese mice. Diabetes 2004; 53 (1): 82-90
36. Jonsson L, Skarphedinsson JO, Skuladottir GV, et al. Food conversion is transiently affected during 4-week chronic administration of melanocortin agonist and antagonist in rats. J Endocrinol 2002; 173 (3): 517-23
37. Brown KS, Gentry RM, Rowland NE. Central injection in rats of alpha-melanocyte-stimulating hormone analog: effects on food intake and brain Fos. Regul Pept 1998; 78 (1-3): 89-94
38. Obici S, Feng Z, Tan J, et al. Central melanocortin receptors regulate insulin action. J Clin Invest 2001; 108 (7): 1079-85
39. Knudtzon J. Effects of pro-opiomelanocortin-derived peptides on plasma levels of glucagon, insulin and glucose. Horm Metab Res 1986; 18 (9): 579-83
40. Knudtzon J. Alpha-melanocyte stimulating hormone increases plasma levels of glucagon and insulin in rabbits. Life Sci 1984; 34 (6): 547-54
41. Butler AA, Marks DL, Fan W, et al. Melanocortin-4 receptor is required for acute homeostatic responses to increased dietary fat. Nat Neurosci 2001; 4 (6): 605-11
42. Campfield LA, Smith FJ, Guisez Y, et al. Recombinant mouse OB protein: evidence for a peripheral signal linking adiposity and central neural networks. Science 1995; 269 (5223): 546-9
43. Hamilton BS, Paglia D, Kwan AY, et al. Increased obese mRNA expression in omental fat cells from massively obese humans. Nat Med 1995; 1 (9): 953-6
44. Cowley MA, Smart JL, Rubinstein M, et al. Leptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus. Nature 2001; 411 (6836): 480-4
45. Licinio J, Caglayan S, Ozata M, et al. Phenotypic effects of leptin replacement on morbid obesity, diabetes mellitus, hypogonadism, and behavior in leptin-deficient adults. Proc Natl Acad Sci U S A 2004; 101 (13): 4531-6
46. Obici S, Zhang BB, Karkanias G, et al. Hypothalamic insulin signaling is required for inhibition of glucose production. Nat Med 2002; 8 (12): 1376-82
47. Lebovitz HE, Genuth S, Pooler K. Relationships between the structure and biological activities of corticotropin and related peptides: hyperglycemic action of N-acetylated corticotropin related peptides. Endocrinology 1966; 79 (3): 635-42
48. Trivedi P, Jiang M, Tamvakopoulos CC, et al. Exploring the site of anorectic action of peripherally administered synthetic melanocortin peptide MT-II in rats. Brain Res 2003; 977 (2): 221-30
49. Born J, Lange T, Kern W, et al. Sniffing neuropeptides: a transnasal approach to the human brain. Nat Neurosci 2002; 5 (6): 514-6
50. Hallschmid M, Benedict C, Born J, et al. Manipulating central nervous mechanisms of food intake and body weight regulation by intranasal administration of neuropeptides in man. Physiol Behav 2004; 83 (1): 55-64